Matinas BioPharma effects 1-for-15 reverse stock split on Sept 28, 2026; CUSIP changes to 576810 402

Matinas BioPharma Holdings, Inc.

Certificate of Amendment filed with Delaware on Sept 25, 2026; split effective 12:01 a.m. ET Sept 28, 2026, with NYSE American trading on a split-adjusted basis at the open.
Every 15 shares of $0.0001 par value common stock converted into 1 share; no fractional shares issued, with holders receiving a proportional cash payment instead.
Par value and authorized share count unchanged; outstanding options, warrants and convertible preferred stock were proportionally adjusted.
Stockholders approved the amendment at the June 23, 2025 annual meeting; the Board authorized the filing on Sept 16, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.